Table 2 HR for HCC.

From: Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B

 

Cohort

PS matched cohort

Tenofovir (ref: Entecavir)

Tenofovir (ref: Entecavir)

HR

95% CI

P-value

HR

95% CI

P-value

Crude model

0.74

0.59

0.92

0.007

0.82

0.64

1.04

0.102

Full model*

0.89

0.71

1.12

0.315

0.87

0.69

1.11

0.274

Main model**

0.82

0.66

1.02

0.078

0.83

0.65

1.06

0.129

IPTW

0.86

0.69

1.06

0.149

    

Additional covariates

Main model + APRI

0.82

0.66

1.02

0.076

0.83

0.65

1.06

0.133

Main model + FIB4

0.83

0.67

1.04

0.106

0.83

0.65

1.05

0.123

Main model + CTP

0.83

0.66

1.03

0.091

0.83

0.65

1.06

0.130

Main model + AFP

0.82

0.66

1.03

0.083

0.83

0.65

1.06

0.137

Main model + CCI

0.81

0.65

1.01

0.065

0.84

0.66

1.06

0.145

Main model + Prior NA+ use

0.86

0.69

1.08

0.189

0.85

0.66

1.09

0.193

Subgroup analysis***

Sex

 Female

0.68

0.40

1.14

0.145

0.72

0.41

1.26

0.246

 Male

0.86

0.67

1.10

0.216

0.85

0.65

1.12

0.248

Age, y/o

 ≤ 50

0.74

0.48

1.14

0.167

0.79

0.48

1.30

0.358

 > 50

0.84

0.65

1.09

0.187

0.86

0.65

1.13

0.271

DM

 No

0.83

0.64

1.07

0.141

0.84

0.64

1.11

0.218

 Yes

0.80

0.51

1.28

0.352

0.78

0.48

1.28

0.328

Liver cirrhosis

 No

0.95

0.60

1.48

0.811

1.08

0.66

1.76

0.775

 Yes

0.78

0.61

1.01

0.061

0.77

0.58

1.01

0.060

Prior NA

 No

0.78

0.60

1.01

0.054

0.79

0.60

1.04

0.095

 Yes

1.25

0.74

2.11

0.406

1.10

0.61

2.01

0.748

Stratified cDDD

 cDDDs ≤ 1095

1.03

0.82

1.31

0.791

1.07

0.83

1.39

0.588

 cDDDs > 1095

0.72

0.36

1.43

0.342

0.59

0.28

1.25

0.170

CTP score

 A

0.92

0.72

1.18

0.530

0.91

0.70

1.19

0.498

 B/C

0.51

0.29

0.89

0.018

0.54

0.30

0.98

0.043

  1. PS propensity score, HR hazard ratio, CT confidence interval, IPTW inverse probability treatment weighting, APRI AST to platelet ratio index, FIB-4 fibrosis index based on 4 factors, CTP Child–Turcotte–Pugh, AFP alpha-fetoprotein, CCI Charlson comorbidity index, NA nucleos(t)ide analogue, DM diabetes mellitus.
  2. *Full model is adjusted for age, sex, liver cirrhosis, DM, APRI, FIB4, CCI, CTP, AST, ALT, platelet, AFP, albumin, bilirubin and INR. **Main model is adjusted for age, sex, liver cirrhosis, DM. ***HRs were estimated by fitting the main model.
  3. +lamivudine, telbivudine, adefovir.
Back to article page